Skip to content

Prevention of Combat-related PTSD Using Attention Bias Modification (ABM): A Randomized Controlled Trial

Prevention of Posttraumatic Symptoms in IDF Soldiers Using Attention Bias Modification (ABM): A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01723215
Enrollment
862
Registered
2012-11-07
Start date
2012-12-31
Completion date
2015-02-28
Last updated
2015-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PTSD

Keywords

Attention bias modification, resilience, combat, PTSD, Depression, Anxiety

Brief summary

Military deployment to combat zones involves exposure to trauma at a higher than average rate and therefore presents a unique opportunity to study predisposing factors to posttraumatic stress reactions and test strategies designed to prevent and ameliorate posttraumatic symptoms. Decades of scientific research on the origins of resilience and vulnerability to combat-related posttraumatic stress symptoms revealed various predisposing and protective factors. All these factors however, offer limited opportunity for systematic pre-deployment prevention efforts. Considering the magnitude of psychological adjustment difficulties encountered by combat personnel in deployment and the limited access to existing evidence-based therapies for PTSD, the development and testing of a novel evidence-based and theory-driven prevention protocol for these problems is of considerable significance. The current study translates cognitive-neuroscience knowledge and attention bias modification research into a novel computerized training tool that could be easily delivered to soldiers during different stages of the deployment cycle. If proved efficacious in reducing risk for posttraumatic symptoms ABMT could be integrated into the Army's resilience training program. Thus, we propose a longitudinal double-blind randomized controlled study of ABMT in soldiers. We will assess attention bias and symptoms before deployment, will randomly assign soldiers to either 8 ABMT sessions, 4 ABMT sessions, 8 Placebo training sessions, or no training. Following 6 months of deployment to combat zone symptoms will be assessed again.

Interventions

BEHAVIORALActive ABMT8

Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance

BEHAVIORALActive ABMT4

Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance

BEHAVIORALPlacebo

Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns

Sponsors

Medical Corps, Israel Defense Force
CollaboratorOTHER
Walter Reed Army Institute of Research (WRAIR)
CollaboratorFED
Tel Aviv University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 28 Years
Healthy volunteers
Yes

Inclusion criteria

* combat soldiers

Exclusion criteria

* Fluent Hebrew

Design outcomes

Primary

MeasureTime frameDescription
Changes in PTSD symptoms(PCL)Pre-treatment(baseline), after first deployment, 10 days after combat, 4 months after combat1\. pre-treatment 2.after first deployment 3.10 days after combat 4. 4 months after combat
Probable PTSD diagnosis(CAPS)Four months after combatFour months after combat

Secondary

MeasureTime frameDescription
Changes in Depression(PHQ-9)) and Anxiety(STAI)Pre-treatment(baseline), after first deployment, 10 days after combat, 4 months after combat1\. Pre-treatment(baseline) 2.after first deployment 3.10 days after combat 4. 4 months after combat

Other

MeasureTime frameDescription
Attention Bias ScoresPre-traetment baseline and in deploymentAttention bias scores measured in milliseconds using the dot-probe task

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026